Using PARP inhibitors in such a scenario is based on the idea that there is a HR DNA repair defect, but no germline BRCA1/2 mutation in up to 50% of ovarian cancers (7, 11, 46, 55). This evidence concerns the gene BRCA1 and ovarian carcinoma.